|
|
| |
Press Release by GTCBIO in Self-Help / Personal Growth
|
|
Scientists Come Together to Discover Possible Cures for Neurodegenerative Diseases
View all releases by GTCBIO
This press release is about: neurodegenerative, pharmaceuticals, university, research, conditions, organizations, biopharmaceutical, government, burlington, conference, gtcbio
2005-12-27, GTCBIO - GTCbio`s conference on Therapeutic Strategies against Neurodegenerative Conditions will be held October 10-11, 2005 at the Boston Marriott Burlington. Over 30 speakers from academia, industry and government organizations will present during this event.(PRWEB) September 1, 2005 -- More than one million people suffer from neurodegenerative conditions of the central nervous system in the United States alone. Yet there are currently no cures and very few treatments for diseases such as Parkinson`s and Alzheimer`s. On October 10 & 11, 2005, over 30 speakers from academia, industry and government organizations will come together at GTCbio’s conference on Therapeutic Strategies against Neurodegenerative Conditions with the common goal of discovering potential therapies for such conditions. Steven M. Paul, President of Lilly Research Laboratories and Executive Vice President of Eli Lilly & Company, will deliver one of two keynote addresses. Paul has authored or co-authored more than 450 papers and invited book chapters and serves on the editorial boards of numerous scientific journals. He has been listed as one of the most highly cited neuroscientists in the world (1980-2000) by the I.S.I., Philadelphia, PA. Delivering a keynote address on Day 2 entitled “Apoptosis and Neurodegeneration: Death is in the Details” will be Dr. Kevin A. Roth the Director of Neuropathology at the University of Alabama at Birmingham. In addition to his research, clinical and teaching responsibilities, Dr. Roth is an Associate Editor for the American Journal of Pathology and the Journal of Histochemistry and Cytochemistry. The conference will also feature presentations from Amgen, Bucks Institute for Age Research, The Biologics Consulting Group, The Burnham Institute, Columbia University, Curis Inc., Elan Pharmaceuticals, Eli Lilly & Company, En Vivo Pharmaceuticals, GlaxoSmithKline, Guilford Pharmaceuticals, Harvard Medical School, Lundbeck, Memory Pharmaceuticals, Merck Research Laboratories, Neuroventures, NIHM-NIH, NINDS-NIH, Oxford Bioscience Partners, Palmer & Dodge, Pfizer Global Research, Recombinant Capital Inc., Rinat Neuroscience, PsychoGenics Inc., Satori Pharmaceuticals Inc., University of North Texas, University of Texas at Dallas, University of Ottawa and Wyeth Research. The event is presented by GTCbio and will take place at the Boston Marriott Burlington in Burlington, Massachusetts. More information including a detailed agenda, exhibitor opportunities and registration information can be found at http://www.gtcbio.com/indexpr1.asp. About GTCbio GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community. GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002. Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax,
Source: PR Web™
|
|
|
|
|
Browse Press Releases: 0-9
A B
C D
E F
G H
I J
K L
M N
O P
Q R
S T
U V
W X
Y Z
|
|
|
« December,2005
|
| S |
M |
T |
W |
T |
F |
S |
|
|
|
|
1 |
2 |
3 |
| 4 |
5 |
6 |
7 |
8 |
9 |
10 |
| 11 |
12 |
13 |
14 |
15 |
16 |
17 |
| 18 |
19 |
20 |
21 |
22 |
23 |
24 |
| 25 |
26 |
27 |
28 |
29 |
30 |
31 |
|
|